<SEC-DOCUMENT>0000078003-23-000099.txt : 20231013
<SEC-HEADER>0000078003-23-000099.hdr.sgml : 20231013
<ACCEPTANCE-DATETIME>20231013173020
ACCESSION NUMBER:		0000078003-23-000099
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231013
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231013
DATE AS OF CHANGE:		20231013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		231325787

	BUSINESS ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192
		BUSINESS PHONE:		2127332323

	MAIL ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pfe-20231013.htm
<DESCRIPTION>PFIZER 8-K OCTOBER 13 2023
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:c6a7d467-3d72-4ed3-85d2-fc65f6b97a65,g:70a51292-b16d-4b2e-befc-dc6f5e5483bf,d:67345b66551c41ad8b184aedc8c15e1b--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:pfe="http://www.pfizer.com/20231013" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pfe-20231013</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0000078003</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-28">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pfe-20231013.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-13</xbrli:startDate><xbrli:endDate>2023-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-13</xbrli:startDate><xbrli:endDate>2023-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-13</xbrli:startDate><xbrli:endDate>2023-10-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i67345b66551c41ad8b184aedc8c15e1b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-2">8-K</ix:nonNumeric></ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4">October 13, 2023</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-5"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">PFIZER INC</ix:nonNumeric></ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-8">1-3619</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">13-5315170</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.75pt"><tr><td style="width:1.0pt"></td><td style="width:91.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">66 Hudson Boulevard East</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">10001-2192</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-13">New York</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">212</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">733-2323</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.005%"><tr><td style="width:1.0%"></td><td style="width:40.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.791%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-19">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-20">Common Stock, $.05 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-21">PFE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-23">1.000% Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-24">PFE27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-25">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company &#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-26">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.853%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02.  Results of Operations and Financial Condition.     </span></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On October 13, 2023, Pfizer Inc. (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pfizer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) issued a press release providing an update to Pfizer&#8217;s previously issued guidance for full year 2023 and other information regarding the Company&#8217;s performance in the third quarter of 2023. A copy of the press release is furnished as Exhibit 99 hereto and is incorporated herein by reference.</span></div><div style="padding-left:2.25pt"><span><br/></span></div><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information furnished pursuant to this &#8220;Item 2.02 &#8211; Results of Operations and Financial Condition&#8221;, including Exhibit 99, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or the Securities Act of 1933, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities Act&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.</span></div></td></tr><tr style="height:12pt"><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.05.  Costs Associated with Exit or Disposal Activities. </span></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the fourth quarter of 2023, Pfizer announced that, to realign Pfizer&#8217;s costs with its longer-term revenue expectations, Pfizer launched a multi-year, enterprise-wide cost realignment program (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Realignment Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). </span></div><div style="padding-left:2.25pt"><span><br/></span></div><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Cost Realignment Program is expected to deliver targeted savings of at least $3.5 billion, of which $1.0 billion is expected to be realized in 2023 and an additional $2.5 billion is expected to be realized in 2024. The one-time costs to achieve the savings associated with the Cost Realignment Program are expected to be approximately $3.0 billion, of which the majority is expected to be cash. These costs will primarily include severance and implementation costs. The estimate of costs that Pfizer expects to incur, and the timing thereof, are subject to a number of assumptions and actual results may differ from current expectations. Pfizer may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Cost Realignment Program.</span></div></td></tr><tr style="height:12pt"><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 7.01.  Regulation FD Disclosure.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On October 13, 2023, Pfizer issued a press release regarding, among other things, an amended supply agreement with the U.S. government for Paxlovid and the preceding items. A copy of the press release is furnished as Exhibit 99 hereto and is incorporated herein by reference.</span></div><div style="padding-left:2.25pt"><span><br/></span></div><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information furnished pursuant to this &#8220;Item 7.01 &#8211; Regulation FD Disclosure&#8221;, including Exhibit 99, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or the Securities Act, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing. </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.853%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01.  Financial Statements and Exhibits. </span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Exhibits</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit Description</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex99_pressrelease1013.htm">Press Release of Pfizer Inc. dated October </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex99_pressrelease1013.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex99_pressrelease1013.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex99_pressrelease1013.htm">, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="15" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cautionary Statement Regarding Forward-Looking Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">This Current Report on Form 8-K and any documents referred to in this communication contain certain &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Pfizer&#8217;s efforts to combat COVID-19, Paxlovid (including an amended supply agreement with the U.S. government for Paxlovid, anticipated timing of commercialization and potential benefits), Pfizer&#8217;s and BioNTech&#8217;s COVID-19 vaccines, defined collectively herein as Comirnaty (including potential benefits), Pfizer&#8217;s anticipated operating and financial performance and expectations for Pfizer&#8217;s product pipeline, in-line products and product candidates (including revenue contribution and projections), utilization rates and an enterprise-wide cost realignment program (including anticipated costs, savings and potential benefits) that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of Paxlovid and Comirnaty; uncertainties regarding the commercial success of Pfizer&#8217;s other products or product candidates; the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with pre-clinical and clinical data (including Phase 1/2/3 or Phase 4 data for Paxlovid and Comirnaty or any of Pfizer&#8217;s other products or product candidates) in any of our studies in pediatrics, adolescents, or adults or real world evidence, including the possibility of unfavorable new pre-clinical, clinical or safety data and further analyses of existing pre-clinical, clinical or safety data or further information regarding the quality of pre-clinical, clinical or safety data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; the ability to produce comparable clinical or other results for Paxlovid and Comirnaty or any of Pfizer&#8217;s other products or product candidates, including the rate of effectiveness and/or efficacy, safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial for any such products and additional studies, in real world data studies or in larger, more diverse populations following commercialization; the ability of Comirnaty, any vaccine candidate or any future vaccine to prevent, or Paxlovid or any future COVID-19 treatment to be effective against, COVID-19 caused by emerging virus variants; the risk that use of Comirnaty or Paxlovid will lead to new information about efficacy, safety or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program, Paxlovid or other COVID-19 programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from existing or future pre-clinical and clinical studies; whether and when any drug applications or submissions to request emergency use or conditional marketing authorization for any potential indications for Paxlovid or any of Pfizer&#8217;s other products or product candidates may be filed in particular jurisdictions and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when submissions to request emergency use or conditional marketing authorizations for Comirnaty or any future vaccines in additional populations, for a potential booster dose for Comirnaty, any vaccine candidate or any potential future vaccines (including potential future annual boosters or re-vaccinations), and/or biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for Comirnaty, any vaccine candidates or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorizations or licenses, or existing emergency use authorizations, will expire or terminate; whether and when any applications that may be pending or filed for Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates (including any requested amendments to the emergency use or conditional marketing authorizations) may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates for any such indications will be commercially successful; intellectual property and other litigation; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates, including the authorization or approval of products or therapies developed by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers, including our relationship with BioNTech; the risk that demand for Paxlovid, Comirnaty or any of Pfizer&#8217;s other products may be reduced, no longer exist or not meet expectations, which may lead to reduced revenues, excess inventory on-hand and/or in the channel which, for Paxlovid and Comirnaty, has resulted in a significant inventory write-off in the third quarter of 2023 and could continue to result in inventory write-offs or other unanticipated changes; challenges related to and uncertainties regarding the timing of a transition to the commercial market for any of our products, and in particular, Paxlovid; uncertainties related to the public&#8217;s adherence to vaccines and boosters; risks related to our ability to achieve our revenue forecasts for Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates; the risk that other companies may produce superior or competitive products; risks related to the availability of raw materials to manufacture or test Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates; challenges related to our vaccine&#8217;s formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or potential future annual boosters or re-vaccinations or new variant-based or next generation vaccines or potential combination respiratory vaccines or next generation COVID-19 treatments;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">the risk that we may not be able to recoup costs associated with our R&amp;D and manufacturing efforts; risks associated with any changes in the way we approach or provide research funding for the BNT162 program, Paxlovid or any other COVID-19 program; challenges and risks associated with the pace of our development programs; the risk that we may not be able to maintain manufacturing capacity or access to logistics or supply channels commensurate with global demand, which would negatively impact our ability to supply our COVID-19 or other products; whether and when additional supply or purchase agreements will be reached or existing agreements will be completed or renegotiated; uncertainties regarding the ability to obtain recommendations from vaccine or treatment advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; pricing and access challenges; challenges related to public confidence in, or awareness of Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates; uncertainties around future changes to applicable healthcare policies and guidelines issued by the U.S. federal government in connection with the declared termination of the federal government&#8217;s COVID-19 public health emergency as of May 11, 2023; trade restrictions; potential third party royalties or other claims; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer&#8217;s business and prospects, adverse developments in Pfizer&#8217;s markets, or adverse developments in the U.S. or global </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">capital markets, credit markets, regulatory environment or economies generally; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; competitive developments; uncertainties regarding the impact, success and associated costs of our enterprise-wide cost realignment  program; and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">You should carefully consider the foregoing factors and the other risks and uncertainties that affect the business of Pfizer described in the &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; sections of its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed by Pfizer from time to time with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">and www.pfizer.com. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. You are cautioned not to put undue reliance on forward-looking statements, and Pfizer assumes no obligation to, and does not intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. Pfizer does not give any assurance that it will achieve its expectations. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i67345b66551c41ad8b184aedc8c15e1b_83"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PFIZER INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Margaret M. Madden</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margaret M. Madden</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Corporate Secretary</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Governance Counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: October 13, 2023</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99_pressrelease1013.htm
<DESCRIPTION>EX-99 PRESS RELEASE OCT. 13. 2023
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i597472341eca46b587874d75c05b6da9_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:9pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">EXHIBIT 99</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><img alt="logo1.jpg" src="logo1.jpg" style="height:67px;margin-bottom:5pt;vertical-align:text-bottom;width:166px"></div><div style="padding-left:9pt"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:5.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:16.8pt;padding-right:107pt"><font><br></font></div><div style="padding-left:3.5pt;padding-right:107pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For Immediate Release </font></div><div style="padding-left:3.5pt;padding-right:107pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">October 13, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div style="padding-left:103.5pt;text-indent:-90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;Media Contact&#58;      PfizerMediaRelations&#64;Pfizer.com</font></div><div style="margin-bottom:0.2pt;padding-left:103.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;+1 (212) 733-1226</font></div><div style="padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Investor Contact&#58;      IR&#64;Pfizer.com</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">+1 (212) 733-4848</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> </font></div></td></tr></table></div><div style="padding-left:9pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Pfizer Amends U.S. Government Paxlovid Supply Agreement and</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Updates Full-Year 2023 Guidance</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:174%"></font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:13.43pt">Removes a Significant Uncertainty by Providing Pathway to U.S. Commercialization of Paxlovid on January 1, 2024 with Amended Supply Agreement</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">In a </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Non-Cash</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Transaction, U.S. Government to Return Estimated 7.9 Million EUA-Labeled Paxlovid Treatment Courses at end of 2023 and Receive Credit for Future NDA-labeled Treatment Courses from Pfizer</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Credit will Support a Patient Assistance Program to Provide Paxlovid Free of Charge to Federally Insured Patients through 2024, and Uninsured&#47;Underinsured Patients through 2028, with Pfizer to Recognize Revenue as Product is Delivered</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Pfizer to Commercialize Paxlovid for the Treatment of Privately Insured Commercial Patients with Prices to be Negotiated with Payers</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Pfizer to Provide U.S. Government with 1.0 Million Treatment Courses for a Strategic National Stockpile</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:174%"></font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:13.43pt">Updates Full-Year 2023 Guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">  </font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Revises 2023 Revenue Guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Range to $58.0 to $61.0 Billion Solely due to COVID Products </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Reduces Guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> for Paxlovid Revenues by Approximately $7.0 Billion, which includes a $4.2 Billion </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Non-Cash</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Revenue Reversal for the Return of Approximately 7.9 Million Treatment Courses of EUA-Labeled U.S. Government Inventory</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Reduces Guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> for Comirnaty Revenues by Approximately $2.0 Billion</font></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Records $5.5 Billion </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Non-Cash</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Charge in 2023 Third Quarter Primarily for COVID Inventory Write-Offs due to Lower-Than-Expected Demand </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Reaffirms Full-Year 2023 Non-COVID Product Operational Revenue Growth Expectations of 6% to 8%</font></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Launches Enterprise-Wide Cost Realignment Program Expected to Deliver Targeted Savings of at least $3.5 Billion, of which Approximately $1.0 Billion is Expected to be Realized in 2023 and at least $2.5 Billion is Expected to be Realized in 2024</font></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.94pt">Revises 2023 Adjusted</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Diluted EPS Guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> to $1.45 to $1.65 to Account for Lower Expected Revenues for COVID Products and Inventory Write-Offs, Partially Offset by $1.0 Billion of Anticipated 2023 Cost Reductions</font></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:174%"></font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:13.43pt">Pfizer to hold analyst and investor call at 8 a.m. EDT Monday, October 16, 2023</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:2.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">NEW YORK, NY, October 13, 2023</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> - Pfizer Inc. (NYSE&#58;PFE) today announced that it has amended its supply agreement with the U.S. government for Paxlovid, the first oral antiviral pill approved by the U.S. Food and Drug Administration (FDA) and is updating its Full-Year 2023 Guidance. </font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Paxlovid Amended Agreement with U.S. Government Facilitates Commercialization</font></div><div style="padding-left:2.15pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">At the end of 2023, Pfizer will accept a </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">non-cash</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> return of any remaining Emergency Use Authorized (EUA)-labeled U.S. government inventory, estimated to be 7.9 million treatment courses, and in the fourth quarter, will reverse the associated revenues currently estimated to be approximately $4.2 billion. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The commercial transition will begin in November 2023, as the U.S. government begins to discontinue the distribution of EUA-labeled Paxlovid. Pfizer will ensure commercial readiness by providing NDA-labeled commercial supply to all channels by the end of 2023, however, EUA-labeled Paxlovid will remain available free-of-charge to all eligible patients until the end of the year, and therefore Pfizer expects only minimal uptake of NDA-labeled commercial product before January 1, 2024.</font></div><div style="padding-left:2.15pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Any remaining EUA-labeled treatment courses previously purchased by the U.S. government will be converted to a volume-based credit. This credit will support continued access to Paxlovid through a patient assistance program (PAP) operated by Pfizer on behalf of the U.S. government. As part of the PAP, all federally insured patients (Medicare and Medicaid) and the uninsured will receive Paxlovid, free of charge, through 2024. Beginning in 2024, Pfizer will sell Paxlovid to privately insured patients (commercial) with prices to be negotiated with payers and offer a copay program through 2028. The PAP will continue to provide access to Paxlovid to eligible uninsured and underinsured patients through that same period. </font></div><div style="padding-left:2.15pt"><font><br></font></div><div style="padding-left:2.15pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Additionally, Pfizer will manage and supply 1.0 million treatment course U.S. Strategic National Stockpile (SNS) to enable future pandemic preparedness and refresh stock prior to expiry through 2028. </font></div><div style="margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Pfizer will recognize revenues as product is delivered beginning in 2024. </font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:0.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Updates Outlook for COVID-19 Products </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Pfizer also announced additional clarity on its full-year 2023 outlook for its COVID products &#8211; Comirnaty and Paxlovid. Clarity on the underlying vaccination and treatment rates will be observed by year end and will set a reliable base for the prediction of future product utilization.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As previously announced, the European Union (EU) contract for Comirnaty supply was renegotiated with amended purchasing obligations through 2026. The U.S. market for Comirnaty transitioned to commercially available product in September 2023. Due to the recent commencement of the fall vaccination period, the outlook for year-end vaccination rates and market shares requires more time for more determinable estimates. </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As previously announced, Paxlovid also received full NDA approval from the FDA earlier this year. The global utilization rates for Paxlovid are currently trending slightly above last year&#8217;s utilization but lower than our original expectations.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Launches Cost Realignment Program </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">In addition, in the fourth quarter of 2023, Pfizer announced that the company has launched a multi-year, enterprise-wide cost realignment program that will realign its costs with its longer-term revenue expectations. The program is expected to deliver targeted savings of at least $3.5 billion, of which $1.0 billion is expected to be realized in 2023 and an additional $2.5 billion is expected to be realized in 2024. The one-time costs to achieve the savings associated with the new cost realignment program are expected to be approximately $3.0 billion, of which the majority is expected to be cash. These costs will primarily include severance and implementation costs. Pfizer will continue to refine the estimated targeted savings and their associated costs over the remainder of the year and will incorporate them into its full-year guidance for 2024.</font></div><div style="margin-bottom:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Updates Full-Year 2023 Revenue and Adjusted</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"> Diluted EPS Guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"> Ranges </font></div><div style="margin-bottom:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Pfizer also announced that it now anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion solely due to its COVID products. Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be approximately $12.5 billion, a decline of $9.0 billion versus original expectations. The company is reducing its full-year 2023 revenue expectations for Paxlovid by approximately $7.0 billion which includes a </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">non-cash</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> $4.2 billion revenue reversal for the return of the 7.9 million treatment courses of EUA-labeled U.S. government inventory, as well as the delayed commercialization to January 2024 versus our previous expectation of commercialization in the second half of 2023. The company is also reducing its full-year 2023 revenue expectations for Comirnaty by approximately $2.0 billion due to lower-than-expected vaccination rates. </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Pfizer&#8217;s non-COVID products remain on track to achieve an expected 6% to 8% operational revenue growth year over year in 2023. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Due to lower-than-expected utilization for our COVID products, Pfizer recorded a </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">non-cash</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> charge of $5.5 billion to Cost of Goods Sold in the third quarter of 2023 primarily related to inventory write-offs for Paxlovid of $4.6 billion and to a lesser extent for inventory write-offs and other charges for Comirnaty of $0.9 billion.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The company expects to deliver approximately $1.0 billion in savings in 2023 through its cost realignment program.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Revised guidance also reflects anticipated improvement in our Effective Tax Rate on Adjusted</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Income for 2023 from approximately 15% in our original guidance to approximately 12%.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Due to the aforementioned items, the company now expects full-year 2023 Adjusted</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> diluted EPS to be in the range of $1.45 to $1.65 versus its original guidance range of $3.25 to $3.45. </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The Company&#8217;s updated Revenues</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">and Adjusted</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> diluted EPS guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> is presented below.</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023<br>Previous Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(August 1, 2023)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">One-Time</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All Other Adjustments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023<br>Revised Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Revenues*</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$67.0 to $70.0 billion</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">-$(4.2) billion</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#126;$(4.8) billion</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$58.0 to $61.0 billion</font></td></tr><tr><td colspan="3" style="border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Non-cash</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Inventory Write-offs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$5.5 billion</font></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2.5pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:2.5pt double #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Diluted EPS*</font></div></td><td colspan="3" style="border-bottom:2.5pt double #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$3.25 to $3.45</font></td><td colspan="3" style="border-bottom:2.5pt double #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$(1.46)</font></td><td colspan="3" style="border-bottom:2.5pt double #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$(0.34)</font></td><td colspan="3" style="border-bottom:2.5pt double #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$1.45 to $1.65</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">One-time items include approximately $4.2 billion of a </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:133%">non-cash</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> revenue reversal related to the return of an estimated 7.9 treatment courses of U.S. government EUA-labeled Paxlovid and a </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:133%">non-cash</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> $5.5 billion inventory write-off of COVID products.</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(b)  All other adjustments include approximately $4.8 billion reduction in COVID product revenue due to the delayed commercialization of Paxlovid to January 2024 versus our previous expectation of commercialization in second half of 2023 as well as lower-than-expected vaccination rates for Comirnaty partially offset by $1.0 billion in anticipated savings from the cost realignment program. </font></div><div style="margin-bottom:3pt;padding-left:9.35pt;text-indent:-9.35pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">*  </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Changes in foreign exchange rates have had a minimal incremental impact since full-year 2023 guidance was issued. Please refer to Press Release Footnote (1) for additional information.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Executive Commentary</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Dr. Albert Bourla, Pfizer Inc. Chairman and Chief Executive Officer, stated&#58; &#8220;Pfizer&#8217;s non-COVID product portfolio remains strong, and we continue to expect these products to achieve year-over-year operational revenue growth in the range of 6% to 8% in 2023.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8220;At the same time, this agreement with the U.S. government makes it easier for patients to access Paxlovid&#59; enables the United States to have a robust stockpile for future use&#59; and provides Pfizer with greater clarity regarding the transition to a commercial market for this important treatment, which has helped remove some of the uncertainty around our business expectations for our COVID products. We expect additional clarification on global vaccination and treatment rates by the end of the year, which we expect will be a good predictor of utilization in future years.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8220;We remain proud that our scientific breakthroughs played a significant role in getting the global health crisis under control. Over the past several years, we have continued to ensure supply readiness for our COVID products, and as we gain additional clarity around vaccination and treatment rates for COVID, we will be better able to estimate the appropriate level of supply to meet demand and continue to address any ongoing public health needs. As a result, we continue to expect our COVID-related revenues to contribute to our business in future periods, helping us to further invest in activities that drive Pfizer&#8217;s long-term growth potential.&#8221;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Pfizer intends to provide additional commentary and all components of its updated full-year 2023 guidance in its Third-Quarter 2023 Performance Report to be issued on Tuesday, October 31, 2023. </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Investor Call Details</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Pfizer Inc. invites investors and the general public to view and listen to a webcast of a live conference call with investment analysts at 8 a.m. EDT on Monday, October 16, 2023.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">To view and listen to the webcast visit Pfizer&#8217;s web site at www.pfizer.com&#47;investors. Information on accessing and pre-registering for the webcast, including dial-in numbers, will be available at www.pfizer.com&#47;investors and participants are advised to pre-register in advance of the conference call. </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The transcript and webcast replay of the call with be made available on Pfizer&#8217;s web site at www.pfizer.com&#47;investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"># # #</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues and acquired in-process R&#38;D (IPR&#38;D) expenses) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.</font></div><div style="margin-bottom:8pt;padding-left:36pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Financial guidance for full-year 2023 reflects the following&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Exchange rates assumed are a blend of actual rates in effect through the second quarter of 2023 and end of September 2023 rates for the remainder of the year. Financial guidance reflects the anticipated unfavorable impact of approximately $1.0 billion on revenues and approximately $0.19 on Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> diluted EPS as a result of changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2022.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Guidance for Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.72 billion shares, and assumes no share repurchases in 2023.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and Reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. See the Non-GAAP Financial Measure&#58; Adjusted Income section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer&#8217;s 2022 Annual Report on Form 10-K for a definition of each component of Adjusted income as well as other relevant information.</font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:5pt"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:237%;text-decoration:underline">INDICATION, AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION FOR PAXLOVID</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">U.S. Indication</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">Limitations of Use</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">U.S. FDA Emergency Use Authorization</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of PAXLOVID for the treatment of adults and pediatric patients (12 years of age and older weighing at least 40 kg) with mild to moderate coronavirus disease 2019 (COVID-19) and who are at high risk for progression to severe COVID-19, including hospitalization or death.</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. &#167; 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">IMPORTANT SAFETY INFORMATION</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">WARNING&#58; SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;padding-left:14.5pt">PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;padding-left:14.5pt">Prior to prescribing PAXLOVID&#58; 1) Review all medications taken by the patient to assess potential drug-drug interactions with a strong CYP3A inhibitor like PAXLOVID and 2) Determine if concomitant medications require a dose adjustment, interruption, and&#47;or additional monitoring</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;padding-left:14.5pt">Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">PAXLOVID is&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">contraindicated in patients with a history of clinically significant hypersensitivity reactions</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;(eg, toxic epidermal necrolysis or Stevens-Johnson syndrome) to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue PAXLOVID and initiate appropriate medications and&#47;or supportive care.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">PAXLOVID is&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">contraindicated with drugs that are primarily metabolized by CYP3A and for which elevated concentrations are associated with serious and&#47;or life-threatening reactions and drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">. There are certain other drugs for which concomitant use with PAXLOVID should be avoided and&#47;or dose adjustment, interruption, or therapeutic monitoring is recommended. Drugs listed here are a guide and not considered a comprehensive list of all drugs that may be contraindicated with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor like PAXLOVID.</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Drugs that are primarily metabolized by CYP3A for which elevated concentrations are associated with serious and&#47;or life-threatening reactions&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Alpha 1-adrenoreceptor antagonist&#58; alfuzosin</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Antianginal&#58; ranolazine</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Antiarrhythmic&#58; amiodarone, dronedarone, flecainide, propafenone, quinidine</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Anti-gout&#58; colchicine (in patients with renal and&#47;or hepatic impairment)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Antipsychotics&#58; lurasidone, pimozide</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Benign prostatic hyperplasia agents&#58; silodosin</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Cardiovascular agents&#58; eplerenone, ivabradine</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Ergot derivatives&#58; dihydroergotamine, ergotamine, methylergonovine</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">HMG-CoA reductase inhibitors&#58; lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Immunosuppressants&#58; voclosporin</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Microsomal triglyceride transfer protein inhibitor&#58; lomitapide</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Migraine medications&#58; eletriptan, ubrogepant</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Mineralocorticoid receptor antagonists&#58; finerenone</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Opioid antagonists&#58; naloxegol</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">PDE5 inhibitor&#58; sildenafil (Revatio</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">) when used for pulmonary arterial hypertension</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Sedative&#47;hypnotics&#58; triazolam, oral midazolam</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Serotonin receptor 1A agonist&#47;serotonin receptor 2A antagonist&#58; flibanserin</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Vasopressin receptor antagonists&#58; tolvaptan</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Drugs that are strong CYP3A inducers</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#58; PAXLOVID cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Anticancer drugs&#58; apalutamide<br>Anticonvulsant&#58; carbamazepine, phenobarbital, primidone, phenytoin</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Antimycobacterials&#58; rifampin, rifapentine</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Cystic fibrosis transmembrane conductance regulator potentiators&#58; lumacaftor&#47;ivacaftor</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Herbal Products&#58; St. John&#8217;s Wort (</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">hypericum perforatum</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">)</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Risk of Serious Adverse Reactions Due to Drug Interactions&#58;&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Initiation of PAXLOVID, which contains ritonavir, a strong CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving PAXLOVID, may increase plasma concentrations of medications metabolized by CYP3A. Medications that induce CYP3A may decrease concentrations of PAXLOVID. These interactions may lead to&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Loss of therapeutic effect of PAXLOVID and possible development of viral resistance</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Severe, life-threatening, and&#47;or fatal adverse reactions due to drug interactions have been reported in patients treated with PAXLOVID. The most commonly reported concomitant medications resulting in serious adverse reactions were calcineurin inhibitors (eg, tacrolimus, cyclosporine), followed by calcium channel blockers.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Hepatotoxicity&#58;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering PAXLOVID to patients with&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">pre-existing liver diseases, liver enzyme abnormalities, or hepatitis</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Because nirmatrelvir is coadministered with ritonavir, there may be a&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">risk&#160;ofHIV-1 developing resistance to HIV protease inhibitors</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;in individuals with uncontrolled or undiagnosed HIV-1 infection.</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The most common</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">&#160;adverse reactions</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;in the PAXLOVID group (&#8805;1%) that occurred at a greater frequency than in the placebo group were dysgeusia (5% and &#60;1%, respectively) and diarrhea (3% and 2%, respectively).</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following adverse reactions have been identified during use of PAXLOVID under Emergency Use Authorization&#58;</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Immune System Disorders&#58;&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Anaphylaxis, hypersensitivity reactions<br></font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Skin and Subcutaneous Tissue Disorders&#58;&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Toxic epidermal necrolysis, Stevens-Johnson syndrome<br></font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Nervous System Disorders&#58;&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Headache<br></font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Vascular Disorders&#58;&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Hypertension<br></font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Gastrointestinal Disorders&#58;&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Abdominal pain, nausea, vomiting<br></font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">General Disorders and Administration Site Conditions&#58;&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Malaise</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PAXLOVID is a strong inhibitor of CYP3A, and an inhibitor of CYP2D6, P-gp, and OATP1B1.&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Coadministration of PAXLOVID with drugs that are primarily metabolized by CYP3A and CYP2D6 or are transported by P-gp or OATP1B1 may result in increased plasma concentrations of such drugs and increase the risk of adverse events. Coadministration with other CYP3A substrates may require a dose adjustment or additional monitoring.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Pregnancy&#58;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;Available data on the use of nirmatrelvir during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Published observational studies on ritonavir use in pregnant women have not identified an increase in the risk of major birth defects. Published studies with ritonavir are insufficient to identify a drug-associated risk of miscarriage</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">.&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">There are maternal and fetal risks associated with untreated COVID-19 in pregnancy.</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Lactation&#58;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;There are no available data on the presence of nirmatrelvir in human or animal milk, the effects on the breastfed infant, or the effects on milk production. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir. Limited published data report that ritonavir is present in human milk. There is no information on the effects of ritonavir on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PAXLOVID and any potential adverse effects on the breastfed infant from PAXLOVID or from the underlying maternal condition.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Contraception&#58;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Advise patients using combined hormonal contraceptives to use an effective alternative contraceptive method or an additional barrier method of contraception.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Pediatrics&#58;&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The optimal dose of PAXLOVID has not been established in pediatric patients.</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Systemic exposure of nirmatrelvir increases in renally impaired patients with increase in the severity of renal impairment. No dosage adjustment is recommended in patients with mild renal impairment.&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Reduce the dose of&#160;PAXLOVIDin&#160;patients with moderate renal impairment&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(eGFR &#8805;30 to &#60;60 mL&#47;min).&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PAXLOVID is not recommended in patients with severe renal impairment</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;(eGFR &#60;30 mL&#47;min)&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">or in patients with end-stage renal disease</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;(eGFR &#60;15 mL&#47;min).</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PAXLOVID is not recommended for use in patients with severe hepatic impairment&#160;</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(Child-Pugh Class C)</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Please see&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Full Prescribing Information</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">, including BOXED WARNING and Patient Information</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Click for Fact Sheets&#58;</font></div><div><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">For Consumers&#58;<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">EUA Fact sheet for Patients, Parents, and Caregivers</font></div><div><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">For Healthcare Professionals&#58;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">EUA Fact Sheet for HCPs</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">INDICATION, AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION FOR COMIRNATY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INDICATION</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">COMIRNATY&#174; (COVID-19 Vaccine, mRNA) is a vaccine approved for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.&#160;</font></div><div style="text-align:justify"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">IMPORTANT SAFETY INFORMATION</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">You should</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration:underline">NOT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">receive COMIRNATY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> (COVID-19 Vaccine, mRNA) if you have had a severe allergic reaction to any ingredient of COMIRNATY or a previous dose of a Pfizer-BioNTech COVID-19 vaccine&#160;</font></div><div style="padding-left:18pt;padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">There is a remote chance that COMIRNATY could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of the vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">If you or your pre-teen or teenager experience a severe </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">allergic reaction, call 9-1-1 or go to the nearest hospital. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Signs of a severe allergic reaction can include&#58;&#160;</font></div><div style="padding-left:49.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:10pt">difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness and weakness&#160;</font></div><div style="padding-left:72pt;padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Authorized or approved mRNA COVID-19 vaccines show increased risks of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart), particularly within the first week following vaccination. For COMIRNATY, the observed risk is highest in males 12 through 17 years of age. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Seek medical attention right away if you have any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">chest pain&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">shortness of breath&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">feelings of having a fast-beating, fluttering, or pounding heart&#160;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Additional symptoms, particularly in children, may include&#58;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Fainting&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Unusual and persistent fatigue or lack of energy&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Persistent vomiting&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Persistent pain in the abdomen&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Unusual and persistent cool, pale skin&#160;&#160;</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Fainting can happen after getting injectable vaccines including COMIRNATY. Your vaccination provider may ask you to sit or lie down for 15 minutes after receiving the vaccine&#160;</font></div><div style="padding-left:22.5pt;padding-right:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">People with weakened immune systems may have a reduced immune response to COMIRNATY&#160;</font></div><div style="padding-left:18pt;padding-right:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">COMIRNATY may not protect all vaccine recipients&#160;</font></div><div style="padding-right:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;padding-left:14.5pt">Tell your vaccination provider about all of your medical conditions, including if you&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:19pt">have any allergies&#160;</font></div><div style="padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:19pt">have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)&#160;</font></div><div style="padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:19pt">have a fever&#160;</font></div><div style="padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:19pt">have a bleeding disorder or are on a blood thinner&#160;</font></div><div style="padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:19pt">are immunocompromised or are on a medicine that affects the immune system&#160;</font></div><div style="padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:19pt">are pregnant, plan to become pregnant, or are breastfeeding&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:19pt">have received another COVID-19 vaccine&#160;</font></div><div style="padding-left:58.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:19pt">have ever fainted in association with an injection&#160;</font></div><div style="padding-left:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">The </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">most commonly reported adverse reactions</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> (&#8805;10%) after a dose of COMIRNATY were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever&#8239;(up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).&#160;</font></div><div style="padding-left:18pt;padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">These may not be all the possible side effects of the vaccine. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away.&#160;</font></div><div style="padding-left:18pt;padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:18pt;padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">You should always ask your healthcare providers for medical advice about adverse events. Report vaccine side effects to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1</font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:10pt;font-weight:400;line-height:174%">&#8208;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">800</font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:10pt;font-weight:400;line-height:174%">&#8208;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">822</font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:10pt;font-weight:400;line-height:174%">&#8208;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">7967 or report online to </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">www.vaers.hhs.gov&#47;reportevent.html</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">. You can also report side effects to Pfizer Inc. at </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">www.pfizersafetyreporting.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> or by calling 1-800-438-1985.&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Please </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">click here</font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> for full&#8239;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Prescribing Information for </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">COMIRNATY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">.&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">AUTHORIZED USE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8239;&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Pfizer-BioNTech&#8239;COVID-19&#8239;Vaccine </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(2023-2024 Formula)*</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">is FDA authorized under Emergency Use Authorization (EUA) to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months through 11 years of age.&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">*Hereafter referred to as Pfizer-BioNTech COVID-19 Vaccine&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">EMERGENCY USE AUTHORIZATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months through 11 years of age. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)&#8202;(1) of the FD&#38;C Act unless the declaration is terminated or authorization revoked sooner.&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">IMPORTANT SAFETY INFORMATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">A person should </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;text-decoration:underline">NOT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> get Pfizer-BioNTech COVID-19 Vaccine if they had a severe allergic reaction after a previous dose of any Pfizer-BioNTech COVID-19 vaccine or to any ingredients in these vaccines.&#160;</font></div><div style="padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">There is a remote chance that the vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the vaccine. For this reason, the vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">If your child experiences a severe allergic reaction, call 9-1-1, or go to the nearest hospital</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">. Signs of a severe allergic reaction can include&#58;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:174%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:12pt">difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, or dizziness and weakness&#160;</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following Pfizer-BioNTech COVID-19 vaccines have occurred most commonly in adolescent males 12 through 17 years of age. In most of these individuals, symptoms began within a few days following vaccination. The chance of having this occur is very low.&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Seek medical attention right away if your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">Chest pain&#160;</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">Shortness of breath or difficulty breathing&#160;</font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">Feelings of having a fast-beating, fluttering, or pounding heart&#160;</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Additional symptoms, particularly in children, may include&#58;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Fainting&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Unusual and persistent irritability&#160;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Unusual and persistent poor feeding&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Unusual and persistent fatigue or lack of energy&#160;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Persistent vomiting&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Persistent pain in the abdomen&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Unusual and persistent cool, pale skin&#160;</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:27.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Fainting can happen after getting injectable vaccines, including Pfizer-BioNTech COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination&#160;</font></div><div style="padding-left:27.35pt;padding-right:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:27.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">People with weakened immune systems may have a reduced immune response to Pfizer-BioNTech COVID-19 Vaccine&#160;</font></div><div style="padding-left:27.35pt;padding-right:5.25pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:27.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">The Pfizer-BioNTech COVID-19 Vaccine may not protect everyone&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%;padding-left:14.5pt">Tell your vaccination provider about all of your medical conditions, including if you&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">have any allergies&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">has had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">has a fever&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">has a bleeding disorder or are on a blood thinner&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">is immunocompromised or are on a medicine that affects the immune system&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">is pregnant or is breastfeeding&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">has received another COVID-19 vaccine&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">has ever fainted in association with an injection&#160;</font></div><div style="padding-left:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-left:22.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:10pt">Side effects that have been reported with Pfizer-BioNTech COVID-19 vaccines include&#58;&#8239;&#160;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Severe allergic reactions&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Non-severe allergic reactions such as rash, itching, hives, or swelling of the face&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Myocarditis (inflammation of the heart muscle)&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Pericarditis (inflammation of the lining outside the heart)&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Injection site pain&#47;tenderness&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Tiredness&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Headache&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Muscle pain&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Chills&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Joint pain&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Fever&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Injection site swelling&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Injection site redness&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Nausea&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Feeling unwell&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Swollen lymph nodes (lymphadenopathy)&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Decreased appetite&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Diarrhea&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Vomiting&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Arm pain&#8239;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Fainting in association with injection of the vaccine&#8239;&#160;&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Dizziness&#160;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Irritability&#160;</font></div><div style="padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">These may not be all the possible side effects. Serious and unexpected side effects may occur. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away.&#160;</font></div><div style="padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Report vaccine side effects to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1</font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:10pt;font-weight:400;line-height:174%">&#8208;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">800</font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:10pt;font-weight:400;line-height:174%">&#8208;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">822</font><font style="color:#000000;font-family:'Cambria Math',serif;font-size:10pt;font-weight:400;line-height:174%">&#8208;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">7967 or report online to </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">www.vaers.hhs.gov&#47;reportevent.html</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">. Please include &#8220;Pfizer-BioNTech COVID-19 Vaccine(2023-2024 Formula) EUA&#8221; in the first line of box #18 of the report form.&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">In addition, individuals can report side effects to Pfizer Inc. at </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">www.pfizersafetyreporting.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> or by calling 1-800-438-1985.&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Please click here for </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">Pfizer-BioNTech COVID-19 Vaccine Healthcare Providers Fact Sheet</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> and </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Vaccine Recipient and Caregiver EUA Fact Sheet</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">DISCLOSURE NOTICE&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">The information contained in this release is as of October 13, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">This release contains forward-looking information about Pfizer&#8217;s efforts to combat COVID-19, Paxlovid (including an amended supply agreement with the U.S. government for Paxlovid, anticipated timing of commercialization and potential benefits), Pfizer&#8217;s and BioNTech&#8217;s COVID-19 vaccines, defined collectively herein as Comirnaty (including potential benefits), Pfizer&#8217;s anticipated operating and financial performance and expectations for Pfizer&#8217;s product pipeline, in-line products and product candidates (including revenue contribution and projections), utilization rates and an enterprise-wide cost realignment program (including anticipated costs, savings and potential benefits) that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of Paxlovid and Comirnaty&#59; uncertainties regarding the commercial success of Pfizer&#8217;s other products or product candidates&#59; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as risks associated with pre-clinical and clinical data (including Phase 1&#47;2&#47;3 or Phase 4 data for Paxlovid and Comirnaty or any of Pfizer&#8217;s other products or product candidates) in any of our studies in pediatrics, adolescents, or adults or real world evidence, including the possibility of unfavorable new pre-clinical, clinical or safety data and further analyses of existing pre-clinical, clinical or safety data or further information regarding the quality of pre-clinical, clinical or safety data&#59; risks associated with interim data&#59; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities&#59; the ability to produce comparable clinical or other results for Paxlovid and Comirnaty or any of Pfizer&#8217;s other products or product candidates, including the rate of effectiveness and&#47;or efficacy, safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial for any such products and additional studies, in real world data studies or in larger, more diverse populations following commercialization&#59; the ability of Comirnaty, any vaccine candidate or any future vaccine to prevent, or Paxlovid or any future COVID-19 treatment to be effective against, COVID-19 caused by emerging virus variants&#59; the risk that use of Comirnaty or Paxlovid will lead to new information about efficacy, safety or other developments, including the risk of additional adverse reactions, some of which may be serious&#59; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review&#47;publication process, in the scientific community generally, and by regulatory authorities&#59; whether and when additional data from the BNT162 mRNA vaccine program, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Paxlovid or other COVID-19 programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations&#59; whether regulatory authorities will be satisfied with the design of and results from existing or future pre-clinical and clinical studies&#59; whether and when any drug applications or submissions to request emergency use or conditional marketing authorization for any potential indications for Paxlovid or any of Pfizer&#8217;s other products or product candidates may be filed in particular jurisdictions and if obtained, whether or when such emergency use authorization or licenses will expire or terminate&#59; whether and when submissions to request emergency use or conditional marketing authorizations for Comirnaty or any future vaccines in additional populations, for a potential booster dose for Comirnaty, any vaccine candidate or any potential future vaccines (including potential future annual boosters or re-vaccinations), and&#47;or biologics license and&#47;or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for Comirnaty, any vaccine candidates or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorizations or licenses, or existing emergency use authorizations, will expire or terminate&#59; whether and when any applications that may be pending or filed for Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates (including any requested amendments to the emergency use or conditional marketing authorizations) may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates for any such indications will be commercially successful&#59; intellectual property and other litigation&#59; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and&#47;or other matters that could affect the availability or commercial potential of Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates, including the authorization or approval of products or therapies developed by other companies&#59; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers, including our relationship with BioNTech&#59; the risk that demand for Paxlovid, Comirnaty or any of Pfizer&#8217;s other products may be reduced, no longer exist or not meet expectations, which may lead to reduced revenues, excess inventory on-hand and&#47;or in the channel which, for Paxlovid and Comirnaty, has resulted in a significant inventory write-off in the third quarter of 2023 and could continue to result in inventory write-offs or other unanticipated changes&#59; challenges related to and uncertainties regarding the timing of a transition to the commercial market for any of our products, and in particular, Paxlovid&#59; uncertainties related to the public&#8217;s adherence to vaccines and boosters&#59; risks related to our ability to achieve our revenue forecasts for Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates&#59; the risk that other companies may produce superior or competitive products&#59; risks related to the availability of raw materials to manufacture or test Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates&#59; challenges related to our vaccine&#8217;s formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer&#59; the risk that we may not be able to successfully develop other vaccine </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">formulations, booster treatment courses or potential future annual boosters or re-vaccinations or new variant-based or next generation vaccines or potential combination respiratory vaccines or next generation COVID-19 treatments&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">the risk that we may not be able to recoup costs associated with our R&#38;D and manufacturing efforts&#59; risks associated with any changes in the way we approach or provide research funding for the BNT162 program, Paxlovid or any other COVID-19 program&#59; challenges and risks associated with the pace of our development programs&#59; the risk that we may not be able to maintain manufacturing capacity or access to logistics or supply channels commensurate with global demand, which would negatively impact our ability to supply our COVID-19 or other products&#59; whether and when additional supply or purchase agreements will be reached or existing agreements will be completed or renegotiated&#59; uncertainties regarding the ability to obtain recommendations from vaccine or treatment advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations&#59; pricing and access challenges&#59; challenges related to public confidence in, or awareness of Paxlovid, Comirnaty or any of Pfizer&#8217;s other products or product candidates&#59; uncertainties around future changes to applicable healthcare policies and guidelines issued by the U.S. federal government in connection with the declared termination of the federal government&#8217;s COVID-19 public health emergency as of May 11, 2023&#59; trade restrictions&#59; potential third party royalties or other claims&#59; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer&#8217;s business and prospects, adverse developments in Pfizer&#8217;s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally&#59; uncertainties regarding the impact of COVID-19 on our business, operations and financial results&#59; competitive developments&#59; uncertainties regarding the impact, success and associated costs of our enterprise-wide cost realignment  program&#59; and</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">A further description of risks and uncertainties can be found in Pfizer&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221;, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"># # #</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pfe-20231013.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c6a7d467-3d72-4ed3-85d2-fc65f6b97a65,g:70a51292-b16d-4b2e-befc-dc6f5e5483bf-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20231013" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20231013">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20231013_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20231013_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20231013_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pfizer.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pfe_NotesDue20271.000Member" abstract="true" name="NotesDue20271.000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>pfe-20231013_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c6a7d467-3d72-4ed3-85d2-fc65f6b97a65,g:70a51292-b16d-4b2e-befc-dc6f5e5483bf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20231013.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6314b2af-6702-44de-9127-a4ed948243a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_Security12bTitle_6314b2af-6702-44de-9127-a4ed948243a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_86b4a60a-9d41-4546-8f2c-c50c77f0baa1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_DocumentType_86b4a60a-9d41-4546-8f2c-c50c77f0baa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bf5ef1da-480a-40c3-a542-24175e09b36b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_DocumentPeriodEndDate_bf5ef1da-480a-40c3-a542-24175e09b36b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1e1c85f7-2c0d-400a-9c83-8665ee784de2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityRegistrantName_1e1c85f7-2c0d-400a-9c83-8665ee784de2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_943a125a-5e25-4670-98a5-6385195b0642" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_943a125a-5e25-4670-98a5-6385195b0642" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4a012151-5e4c-45cc-aa64-d4fffd7c4a0e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityFileNumber_4a012151-5e4c-45cc-aa64-d4fffd7c4a0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f8b8b2a7-2423-440d-b0e5-b4c10aee5311" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityTaxIdentificationNumber_f8b8b2a7-2423-440d-b0e5-b4c10aee5311" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fffdc0e3-1090-42d3-b577-6523b39e4b4b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityAddressAddressLine1_fffdc0e3-1090-42d3-b577-6523b39e4b4b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8f271b08-7613-4e2c-bc76-c82ac2f3c262" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityAddressCityOrTown_8f271b08-7613-4e2c-bc76-c82ac2f3c262" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bbb4359c-3eb1-4e9c-b6b8-6ce8d9cf0165" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityAddressStateOrProvince_bbb4359c-3eb1-4e9c-b6b8-6ce8d9cf0165" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_810a42e7-2cc3-4fca-88c8-b2b1eacb0179" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityAddressPostalZipCode_810a42e7-2cc3-4fca-88c8-b2b1eacb0179" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c7edf18f-fe30-49ea-be23-05aec1eff6c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_CityAreaCode_c7edf18f-fe30-49ea-be23-05aec1eff6c5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_504a66e0-e06b-4b8d-afde-2ff07010a157" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_LocalPhoneNumber_504a66e0-e06b-4b8d-afde-2ff07010a157" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_411b2cad-9023-4231-a730-b8b109ba138d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_WrittenCommunications_411b2cad-9023-4231-a730-b8b109ba138d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_9aff0d76-a4e7-40b9-8647-bec8c2503f2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_SolicitingMaterial_9aff0d76-a4e7-40b9-8647-bec8c2503f2f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_abcd6b1e-8d8d-4b87-a250-3d43e53b0ca8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_PreCommencementTenderOffer_abcd6b1e-8d8d-4b87-a250-3d43e53b0ca8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f24da85a-d26c-4598-98bf-b790f45a8737" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f24da85a-d26c-4598-98bf-b790f45a8737" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_868c098a-96d0-4882-82dd-499a9db42c98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityEmergingGrowthCompany_868c098a-96d0-4882-82dd-499a9db42c98" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8c0509c8-1bba-492a-9ea3-cf0703433d82" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_AmendmentFlag_8c0509c8-1bba-492a-9ea3-cf0703433d82" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e905fe79-a3c5-4b56-b1e6-61616192a831" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityCentralIndexKey_e905fe79-a3c5-4b56-b1e6-61616192a831" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2dff6141-a270-4774-8672-d063cb0f4892" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_TradingSymbol_2dff6141-a270-4774-8672-d063cb0f4892" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_de78ae93-8a71-44d1-bfac-d6ff83623e6e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_SecurityExchangeName_de78ae93-8a71-44d1-bfac-d6ff83623e6e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_b3c5bf82-4545-4b66-8d06-20ab5a7ead81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntitiesTable_b3c5bf82-4545-4b66-8d06-20ab5a7ead81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f49600d1-8abd-43da-94be-6ed04c0fc14d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_b3c5bf82-4545-4b66-8d06-20ab5a7ead81" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f49600d1-8abd-43da-94be-6ed04c0fc14d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f49600d1-8abd-43da-94be-6ed04c0fc14d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f49600d1-8abd-43da-94be-6ed04c0fc14d" xlink:to="loc_us-gaap_ClassOfStockDomain_f49600d1-8abd-43da-94be-6ed04c0fc14d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7306b1dd-f340-404f-8f74-7b5033e42b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f49600d1-8abd-43da-94be-6ed04c0fc14d" xlink:to="loc_us-gaap_ClassOfStockDomain_7306b1dd-f340-404f-8f74-7b5033e42b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_879bd803-0d0a-483c-9ef8-9df2847dbec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7306b1dd-f340-404f-8f74-7b5033e42b48" xlink:to="loc_us-gaap_CommonStockMember_879bd803-0d0a-483c-9ef8-9df2847dbec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_fbe994e0-6bb5-4570-adf6-4b4d91aa0ac4" xlink:href="pfe-20231013.xsd#pfe_NotesDue20271.000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7306b1dd-f340-404f-8f74-7b5033e42b48" xlink:to="loc_pfe_NotesDue20271.000Member_fbe994e0-6bb5-4570-adf6-4b4d91aa0ac4" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pfe-20231013_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c6a7d467-3d72-4ed3-85d2-fc65f6b97a65,g:70a51292-b16d-4b2e-befc-dc6f5e5483bf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityInformationLineItems_a0df97ef-3b98-4143-8e7d-47b33b4efaff_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NotesDue20271.000Member_ecf56c65-f307-4c18-b6ba-1195084177c4_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_label_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_documentation_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member" xlink:href="pfe-20231013.xsd#pfe_NotesDue20271.000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20271.000Member" xlink:to="lab_pfe_NotesDue20271.000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_057bf885-ab23-4239-9434-721503a89594_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_398b4d05-9021-4119-b67b-3a10a743c154_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_1bc360d0-5d3d-4e5c-b121-e47a44638206_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9f1c9bf5-048d-4068-81a9-65bad9c62234_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_57d35a89-bd73-45f8-8b13-26db2cec2c97_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_12cebbd4-ff45-42e3-84b1-1d41c6123d55_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_194a5965-9b36-4d76-8bb8-889c1f456604_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d020ec71-b90a-4d2f-89d5-01e2dc24299b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5f099589-b89c-4258-ada2-eba6050b4cce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e7b4a319-10f2-4ed8-9a22-ee2961ec6017_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_7559229b-422c-4b97-bf09-1328fc28b480_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_723fec9a-d354-4d07-a5d4-7a4d30a3309f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a182567c-5a67-42c8-924f-e1ced87efc57_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2f2d1365-e52e-4eef-bb9d-28b267da6f28_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a5ad0704-fdbb-4d3c-9174-1df0e0033a12_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9c071c32-9a47-4405-92de-40ecd61753e7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_548eff43-866a-481e-b154-35701525afd6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9ed3eb37-56a3-428b-936e-4dee9981786b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_55cca163-25a0-4ed0-a290-e4b9b4d032a7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_21099e68-3164-4211-9e1d-19ff12e6744e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_aee36654-fe9f-4af5-ba46-82ed32235a72_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_eb43c96b-e45c-4846-97e4-154be2bd201e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6ccd731b-93b1-41bb-8756-5f4d1e1519dc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_bc75e10b-5347-4711-a483-c9e2e1ab17c5_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_76bda413-303b-438e-9fef-681a03066d59_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0ea20b2a-be75-43f9-8d8c-b592137349d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6a9f4a79-16ff-491f-8db0-96fc5506ed81_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pfe-20231013_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c6a7d467-3d72-4ed3-85d2-fc65f6b97a65,g:70a51292-b16d-4b2e-befc-dc6f5e5483bf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20231013.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5760745e-9be4-45cb-8218-b9a0ce38302e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_b3c5bf82-4545-4b66-8d06-20ab5a7ead81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5760745e-9be4-45cb-8218-b9a0ce38302e" xlink:to="loc_dei_EntitiesTable_b3c5bf82-4545-4b66-8d06-20ab5a7ead81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f49600d1-8abd-43da-94be-6ed04c0fc14d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_b3c5bf82-4545-4b66-8d06-20ab5a7ead81" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f49600d1-8abd-43da-94be-6ed04c0fc14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7306b1dd-f340-404f-8f74-7b5033e42b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f49600d1-8abd-43da-94be-6ed04c0fc14d" xlink:to="loc_us-gaap_ClassOfStockDomain_7306b1dd-f340-404f-8f74-7b5033e42b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_879bd803-0d0a-483c-9ef8-9df2847dbec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7306b1dd-f340-404f-8f74-7b5033e42b48" xlink:to="loc_us-gaap_CommonStockMember_879bd803-0d0a-483c-9ef8-9df2847dbec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_fbe994e0-6bb5-4570-adf6-4b4d91aa0ac4" xlink:href="pfe-20231013.xsd#pfe_NotesDue20271.000Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7306b1dd-f340-404f-8f74-7b5033e42b48" xlink:to="loc_pfe_NotesDue20271.000Member_fbe994e0-6bb5-4570-adf6-4b4d91aa0ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_b3c5bf82-4545-4b66-8d06-20ab5a7ead81" xlink:to="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6314b2af-6702-44de-9127-a4ed948243a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_Security12bTitle_6314b2af-6702-44de-9127-a4ed948243a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_86b4a60a-9d41-4546-8f2c-c50c77f0baa1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_DocumentType_86b4a60a-9d41-4546-8f2c-c50c77f0baa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bf5ef1da-480a-40c3-a542-24175e09b36b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_DocumentPeriodEndDate_bf5ef1da-480a-40c3-a542-24175e09b36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1e1c85f7-2c0d-400a-9c83-8665ee784de2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityRegistrantName_1e1c85f7-2c0d-400a-9c83-8665ee784de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_943a125a-5e25-4670-98a5-6385195b0642" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_943a125a-5e25-4670-98a5-6385195b0642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4a012151-5e4c-45cc-aa64-d4fffd7c4a0e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityFileNumber_4a012151-5e4c-45cc-aa64-d4fffd7c4a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f8b8b2a7-2423-440d-b0e5-b4c10aee5311" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityTaxIdentificationNumber_f8b8b2a7-2423-440d-b0e5-b4c10aee5311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fffdc0e3-1090-42d3-b577-6523b39e4b4b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityAddressAddressLine1_fffdc0e3-1090-42d3-b577-6523b39e4b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8f271b08-7613-4e2c-bc76-c82ac2f3c262" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityAddressCityOrTown_8f271b08-7613-4e2c-bc76-c82ac2f3c262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bbb4359c-3eb1-4e9c-b6b8-6ce8d9cf0165" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityAddressStateOrProvince_bbb4359c-3eb1-4e9c-b6b8-6ce8d9cf0165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_810a42e7-2cc3-4fca-88c8-b2b1eacb0179" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityAddressPostalZipCode_810a42e7-2cc3-4fca-88c8-b2b1eacb0179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c7edf18f-fe30-49ea-be23-05aec1eff6c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_CityAreaCode_c7edf18f-fe30-49ea-be23-05aec1eff6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_504a66e0-e06b-4b8d-afde-2ff07010a157" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_LocalPhoneNumber_504a66e0-e06b-4b8d-afde-2ff07010a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_411b2cad-9023-4231-a730-b8b109ba138d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_WrittenCommunications_411b2cad-9023-4231-a730-b8b109ba138d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_9aff0d76-a4e7-40b9-8647-bec8c2503f2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_SolicitingMaterial_9aff0d76-a4e7-40b9-8647-bec8c2503f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_abcd6b1e-8d8d-4b87-a250-3d43e53b0ca8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_PreCommencementTenderOffer_abcd6b1e-8d8d-4b87-a250-3d43e53b0ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f24da85a-d26c-4598-98bf-b790f45a8737" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f24da85a-d26c-4598-98bf-b790f45a8737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_868c098a-96d0-4882-82dd-499a9db42c98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityEmergingGrowthCompany_868c098a-96d0-4882-82dd-499a9db42c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8c0509c8-1bba-492a-9ea3-cf0703433d82" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_AmendmentFlag_8c0509c8-1bba-492a-9ea3-cf0703433d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e905fe79-a3c5-4b56-b1e6-61616192a831" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_EntityCentralIndexKey_e905fe79-a3c5-4b56-b1e6-61616192a831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2dff6141-a270-4774-8672-d063cb0f4892" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_TradingSymbol_2dff6141-a270-4774-8672-d063cb0f4892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_de78ae93-8a71-44d1-bfac-d6ff83623e6e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_8d00d08b-9d6b-4429-9c5c-5ea117fe9c5d" xlink:to="loc_dei_SecurityExchangeName_de78ae93-8a71-44d1-bfac-d6ff83623e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo1.jpg
<TEXT>
begin 644 logo1.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# *8# 2(  A$! Q$!_\0
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M_!7SXE?\([\$?#?@V"79<^)-4\Z9<_>MK90S C_KK) ?^ FOS8^#O[37Q,^
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C2T6RZ?(RC%*3:1I4445\X:A1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140615829732992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Oct. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 13,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-5315170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">66 Hudson Boulevard East<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001-2192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-2323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.05 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member', window );">Notes Due 2027, 1.000% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>pfe-20231013_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20231013"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pfe-20231013.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0000078003</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-28">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentType contextRef="c-1" id="f-2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-10-13</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-10-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-5">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-8">1-3619</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">13-5315170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">66 Hudson Boulevard East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">10001-2192</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">NY</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="c-1" id="f-14">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">733-2323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-20">Common Stock, $.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-21">PFE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-22">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-23">1.000% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-24">PFE27</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-25">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M8!A@T0DH[N59(J]@572<!Q=@% 4IN@'%3?R3]&!@IBL98^91(=)QW09ST1Y
MBR9 <??^K )C1 P#$T5IO'</74J%"RUXJ 6&5+0 BMOT3(:!%Y@@7I([F.,J
MX&$I#ZY2R5,8/L7=>JI$PX/A$5!DNP6%B'U8E=TO%D?RA^M5DA7N3W&S_HYL
MK'4*9)6 N&PE8.'_]*0&,(J$6MI\_@D*9F4G6\+C;2D:+EB%Q@JS9[@[7\&
M^=F@W89\6;IXQ04J40IK9R=9^Q!@%-C#&)+W0CZ*TO&ID'+L7Z?K..B"_V#%
MC_NP=07HM3,CO6?R]4Y8QRI?Z/\?*WU6&#QS?_BK">KX[R4N.@'#3?PQ,+"
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M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
M@L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V
M&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= 9.
MMO8(72A]95,. 46=W=3%<]0!;\K!XVBLA H#E&^J%977DHHM)]W1ZTSO'R:/
M6D;KW$JY]_!*MAQSCG^T_ %02P,$%     @ R8M-5R0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ R8M-5P=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #)BTU7(RQ3_^X    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( ,F+35<9117U-P$  "<"   /
M  "  <@0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #)BTU7)!Z;HJT
M  #X 0  &@              @ $L$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " #)BTU799!YDAD!  #/ P  $P
M@ $1$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !;%
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pfe-20231013.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="pfe-20231013.htm">pfe-20231013.htm</File>
    <File>pfe-20231013.xsd</File>
    <File>pfe-20231013_def.xml</File>
    <File>pfe-20231013_lab.xml</File>
    <File>pfe-20231013_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pfe-20231013.htm": {
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20231013",
   "dts": {
    "inline": {
     "local": [
      "pfe-20231013.htm"
     ]
    },
    "schema": {
     "local": [
      "pfe-20231013.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "pfe-20231013_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20231013_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20231013_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 28
   },
   "report": {
    "R1": {
     "role": "http://www.pfizer.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pfe-20231013.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pfe-20231013.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "pfe_NotesDue20271.000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pfizer.com/20231013",
     "localname": "NotesDue20271.000Member",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Due 2027, 1.000% [Member]",
        "label": "Notes Due 2027, 1.000% [Member]",
        "documentation": "Notes Due 2027, 1.000% [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000078003-23-000099-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000078003-23-000099-xbrl.zip
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M^*EW.Y RG3& 8"O8Q%M8*0X&RX8V8/SD^.N7DO;T!5Y^/&-0:@0E.W8,2V[
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M5CE_97J??B;RE6FX1_="*_21_@.IP03B@=)!(4;Q>.0Z2^&1F,TZC!B9=?R
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M%G&XCH:I!X)L;&!Z?=E KED.JHER9C9J,Z"+3?AW)L!FGDC/0-9 F6,\8"H
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MC4.7C,,K2[]*<.]M'GI?81Z6<EB;)TQEC"6[F"FT%7-/$54YC4.,GP@VF+.
MTCH3#FR8C06>3%A,O4C-8(H"F#%"8#I2R2P=8QAFBND8#C9!#&$(.AEGHO*
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M$KTH L(P:9B](J>''!/\S C.S^RV]*8A7>B49H0SL-0CX+*6PXQ.'(&.,V4
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MD[!0_#+%:QO=#) -^2\AXM62?3H?HQOO-]O-#JJ#^;5KFBVEBXLM(<EO@WZ
MAKUUF35X'7FE4Y@++2+L"R&0H62 5(9))#3& +4I\ A-Z;DBF\MFB0)[)_!0
M,2S*XN*"DFEI%QB&R>(AOP9_$S-C>&ZYS*!ZP1WH&^$'O$,,H#T+RP.I$)!'
M<YLB%3=2I^;RZTVZH:,2ZHZ3$;^!P;:3W:C7@S5+C]=]*SFQ;>C\-[2S6T1%
M*"V-U=(@LT]0-8#9[41:*O*'P<"P&L!)2=I";#/82@P@.UC4+B,!PIQ7-VM0
M)LJ(C-NKOI70+0J(<E]P!WH)_,2X95AU$_BI#Q[,ZX[C5"P!XJ@<63  9M)9
M,@"+=FUKZZ#+.LEV4?%6%AO"KZ1@';L"0TL2;;05)%/JPJI'W=BV7/)I]9SJ
MX+Z-F6LUPL]W3!)8U!#K_/"H3S*UA02Z=&W[$KRLKAK,-N=[G:9H<6/!4;<<
MPPQ+N?+GM-Y4M$5*FR]EM74.1U.@*"6+:NH \N4 ' W&74,O>5O"-@1,\IL0
MKJ7*-(P-W 297)3WS$0H*Q*43XA*\R+!:>G0)I1UDP\2\!66Q""7UM*VLBQ9
M.#Y6&)2D(#1K <0&MOI7)^8./5-8B)5M ZP+5'C>:I&.]>;\$12Y//TP4[D!
M%<+<[2!FS6DVB/);X%42F"\Q&(]0!])^!=.YFVE>6!'-C0]XBZEPM]Y@,_BY
MHCMF$S(P5; ?SJ[\G3:;7)P=Y<)F 7>](F9FA7*IL6UL+>8 BUV &JK&P7J,
M8OJ_PEX4TZ7G.;7$+/KHA 97T<POMH9V1A6)29A_ -1P=H';!86K.9#/RGR+
M09;+5T.AL<Z<BE7"PD B0_(=B/864JGU0F*-Q"IF8PA!92-$'07-N-'D$$6;
MDO??,@'.#ND=;+=SHUJ(?^)\N?#.$6%\/4.?]:&<D2M\'7M?2>'L+1B)AUEX
MIT14X41@@F/X$)BN6/GCNG:= 'L,$#^*L)XS!OHEOI ]KA);I0DAF01HHMT*
M@@LE%;$$*_[!SP58O\SO1V2KX=S2YEBUQGIA-RKM!76S+F4/-$GPUDX6HDM8
MZ?R.':#H8G'TE9$#VXC'<5:,:G&=9U[ESA>W^_% @I\Q E3HN)YOU+>LT:),
M4YS&8!=;44;+7&FVL0AMPA^=R[.1WIP#.7_RJF:.484E6Y>;MZ\66%V66-J8
M<PMRVUOU^P@WW4=69F9.'1I=K/FV]HJ86XV!/1+(JT9>YD[!L%:ULOATX=%#
ME.ZMH\>X:0:-E(1DM9&OVUV>F!D*Y 5&<R=SV+V!$X )$E79AR><0K$<&CN.
MDT33Y,L7Q5D6_$7G\2/PJ%)RG.D4TI<XF<6EN%&UO[S$UW7B $^^[3DR"XE[
M_#6K@.#RUN"VQ@*K1G,7W!EFT0'MM12[1$."7T42RF)U,W"41X8/@/+ 1I+7
MHA$,?2$^ \Y'?"!,P>>$QQFND$%&%OT(7?8,FCGH /1(MJP4D.,$: VXON8R
MRA&V*H>L"MM0"G\]&HN7(A^+>UD>="#OL^@*^^939(T%O$;@[<$..LM/P"*4
M6F7V$(G%A28>!G\8RRE*)P@EV(C,B"%%2+ 2=>"*;E&' #/J^B*VU=(:4KH7
MP,-V<Q-JEZ*J--AI>50#I%PD?!%3AV)"[OU7FB%K#I1 #Q=ZB!-[\L\86.P'
M,PX48*H>_RN OW-";"<N3JU-M;%&EJ(_A=*:Q-[81*-)ZBRO,9T2B\AT6;_%
MA:[3#7 &29H-#EQ(P)B$82EZY@::@4H(+QD.;[V6P>!,$WA.\,8W<V;''LR!
M-U=TJ N,GL65F!LEA4": JRL%OBS64_C72]'G:L!E")UPLMWV%EK7](U8]MS
MLV.#4&Y%[69;WOH+]V(Y!)U/SY31H^=0)$+"L2W\AN?YGD\.D04]+HA3Z@?G
M4HJ=N*-N1KA-_@)F+@*N%X(ECV8M%C5E0=M)9%U(!Q01759ES=D4]DQRWMT(
M*PA<MH1#IO@L3TW0'E=870L[0)6^ :&K)0UY;9<K[P]# Q8ZUQ$A4Z84C^WB
M1:FDD?C%M!"52(.\\Y&HHU6LYIEX"")*=S': .!O&>"J)2]\B66V1^H#U9_.
M05"DWYWGG*-9-BQ87+Z9H!6SARXH^H9=YMLH[*G6N%NF.1Q;(AFF5_8.##_O
M#^C)&HJ9B]=X VYS3K&X26W0@#B3*TME'$S(.N@")@8PJ=G"RZT7>UH.-.FG
MNG6!TA;L&P]^SRS*)J("QB;)IO;\Z6*X&77EXL]\,CWX0.)9A4LVF[XN5HVJ
M:ZV^VV9F,/[,PFO\NH0K @A%D=<99L:7<*>7%KVEI7#"RH!01?LIP+)RCF37
M>2#</E&*_.6AI<U4;H*[!A9>5'D4<.C>(D)N$I<I@@B\M!4]7HK&4&6!W>:U
MS43IC&+8-,M1E PP8D:@)G<W:&..Q8C;Y+[!MXM;C.T=_YKS*-^B"T-^6Z3.
M=:&PFB.@$'=>!E'@>(Q^CHW"Y][GBF8VIV8:POXI1DE*"W)[ KA$D?&327"1
M4:$+F*![[:P;RDX>>^;AM=2$KW"O"<8&@.+;^"%,*Q^6(;3'L['@$4IPR7NX
M"Z"4((A;B&'A^"Q,]@!/C0>N<,+*12&PZ[8N.SL 8T.3%P.],LFS&5<FQ?$M
M'(S%E>$JR2AW1AN#4W&$,R8^@!IA.!A@V'I*GYZT+,0KQJC&0[NCL8-Y444S
M%"$=V2M5TT@J;8IMG5$I>AH =D.V+'N\R[TL%\I4%[J(%G!BX2?0;]\WU:@'
MB#>-@<+4I5N_?-\RT-EX+BJ90W\V96.15<2ELR'KL]J#3$N7HBH7TD1@$\A1
M+=4Y(0\P?T%U3A:S+(&*A66N] \KK.EN@7J>NBAG/' ^"Z\;4.T2M:M?R1<1
MVEB#]5IFL>5E%K [8=MB?0-0*9D6OY="*2*^EBHQ2HDV'K02S O,+D\'W6[!
M"ZM8[$,Q[4M...NNH,Q%\0M%L.F1@XH;4I; 3<:NY[5#-DGFH( !/Q8"W%D'
M5D ,Z.85;>;365>_5EBENC&BF05'I91:3&N<J!$XH7ETNE0(4P"]_" Y(T]+
MC,"*@]N%&$)>NTW&W*#O&@CK]N-*>A2&*=<&TJ_7=.5+T4W=?/TLS^!:9TZS
M; HX@[Z4BB*#):>(!8?@\*+5G4N!0<%2V",/W!KX/"]%3[(XOV#&"B ZV@4'
M$/'ED;?E&Q6>1:7SOY*,Z;&M753".*1@.;1T9_LQW#%*"/";2'E^=86M'+FM
M*K(4?LUWN.+04DA'^ 8F%%:Z1POK'-E',YJK@L8![./%:O/3<N4 WH5IYWF%
M,T"D<&1F\='@(7N)INO8WI! \T(Y.#)^]$+5M]_R?JJSOYGX&[#(/-;EYW\K
MP=2B,-RD6_+P@$TRX7U*&(S!?ZMURJ7*:G.^V!9KX\?J3.X2="6*"LE'!&<#
M.A@+ ?=G-FL 40U 5P_Y2L-C2]B6&4'RGX!#4UJ.!FQ7[LHH<RT$0*602A+F
MKA"(3MS9FW4GN.H89;IO+;"]1ZE<27!76; ],%!HQ_JC HW\!,;R,[P)@W\!
M08T<>"9X3E<.C\6<Y <O]6@PM 7X6V .>Q0?*9F"%06'(J.T@J2J<5-8L&9(
M8\W=%7YXPQ7=-06.8>2."N!>0QFQQ%Y#A;M,;/8@>R%R_G$3G*>^C?PB/5:]
MF&JQKJCN7"*S&O7*;2I8*1V9RW9H*R&EC?@LOUXKG^J(ZJ/H\T\8!* (,Q6-
MI\:)=D%CM";5B[I>OPORZ$C]KG/KZ]B''U"2.[N=;F^PL]/K^4'7Y^'>P-_K
M<A$&>X'?$_[@/WN=VB.,]6U>^XYGP.B3-Y>G/YX=7?UR<7*Y)5#GU@_TG"^<
M:RI'^S>^KAH;752_WQ1F")!,*22=\E(&*)CZ2<SF":HN0.4?B#&/ABZ 0N=L
M;0,,+&1XLQ)UYQ+"(KPWBOS.MPWM-W9;NP^Y;:C3:>STUC]^\+?H&[W]]J/W
MVMMO='M[#[\1Y\%WE:3)](G.UU:_ZK5T^G7G^5%T_O'TWR<7[/3LN'JH]W>R
M8J\4;2=%K^+W2M&K^+TNUA)%/\S[+X><VRYA:NHF^P38DRN1LD\-^#D,1?P0
M*?VZ+W]O$[]>HD _SAIO/9DO;^%>'D67(L8JR;_+ *\P$9I"O+8VUV6K+D6
MQ\;4_%5*7REZFCNNQE(,V8]4%$-1Y>,DB[6(7@7RE:)MH6C=K>=/$>+]@ G\
M_M*G'1Z61[EG</XE)6Z:@R2<PS_C=!(=_C]02P,$%     @ R8M-5\->(Y4H
M P  L0H  !    !P9F4M,C R,S$P,3,N>'-DU59+4]LP$+[G5Z@^5_$C+^+!
M8:8P=)A)*4-ARHV1K76BP99<22:AO[Z2$A,2$D+:'MI<8NU^WVI?7N_QR;PL
MT"-(Q01/O+ => AX)BCCD\2[O3G'1][)J-4Z_H#QW:?K,3H365T"U^A4 M%
MT8SI*=)30-^%?&"/!%T51.="EAB/'.U45$^23:8:14'4:6"-5L99GPQHMS_
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M[Y:P@SGX\=2V;=RA=4<OG_'%XJ.IQI(WV0U/YU-FH&3"4!"2Q,H^C!*00,Y
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M&J(50] !JS(?M"+!<!=X$H&K*5*3!X8'$6+WD9 GBKM+?/2YU(?ZM*Z^%&7
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M_P-02P$"% ,4    " #)BTU7R8)S$JY'  "=,0( &0              @ $
M    97@Y.5]P<F5S<W)E;&5A<V4Q,#$S+FAT;5!+ 0(4 Q0    ( ,F+35?$
M&W*C)2$  %70   0              "  >5'  !P9F4M,C R,S$P,3,N:'1M
M4$L! A0#%     @ R8M-5\->(Y4H P  L0H  !               ( !.&D
M '!F92TR,#(S,3 Q,RYX<V102P$"% ,4    " #)BTU78*,R_&0(    /
M%               @ &.;   <&9E+3(P,C,Q,#$S7V1E9BYX;6Q02P$"% ,4
M    " #)BTU76.UC;>T,  "$=@  %               @ $D=0  <&9E+3(P
M,C,Q,#$S7VQA8BYX;6Q02P$"% ,4    " #)BTU7>Y.=J1$(  ";/@  %
M            @ %#@@  <&9E+3(P,C,Q,#$S7W!R92YX;6Q02P4&      8
,!@") 0  AHH

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
